At COO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top California based COO’ operating in the Biotechnology space. If you think a COO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Kelly Huang
Chief Operating Officer of Cardea Bio
Follow Kelly Huang:
About Cardea Bio: Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Gene Castagnini
COO, CFO, CAO & Co-founder of Biocare Medical
Gene J. Castagnini, MS, MBA, co-founded Biocare Medical LLC in 1997 and serves as its Co-Owner and Chief Financial Officer. Gene Castagnini serves as the Chief Operating Officer and Executive Vice President of Biocare Medical, LLC Gene Castagnini served as the Chief Administrative Officer and Chief Financial Officer of BioGenex Laboratories. Inc., for 10 years. Gene Castagnini’s experience includes 15 years as a Director and Officer of Medi-Physics Inc., formerly a Hoffmann-La Roche Inc. subsidiary. Gene Castagnini has a BS in accounting and an MBA in Human Resource Management from the California State University school systems.
Follow Gene Castagnini:
About Biocare Medical: Biocare Medical is a provider of immunohistochemistry instrumentation.
Riley Ennis
Co-Founder and COO of Freenome
Riley is a Thiel Fellow who created a cancer vaccine with his previous company Immudicon as Co-Founder & Chair. Co-Founder, COO at Freenome.
Follow Riley Ennis:
About Freenome, Immudicon, Oncolinx, The Thiel Foundation: Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Vivien Chan
COO of Eureka Therapeutics
Vivien Chan serves as the Chief Operating Officer at Eureka Therapeutics.
Follow Vivien Chan:
About Eureka Therapeutics: Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Don Calabria
COO of Endonovo Therapeutics
Don Calabria Chief Operating Officer brings over seventeen years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance, and business development. Mr. Calabria has a deep level of experience in analyzing companies, determining the operational efficiencies, and conducting operational due diligence on targeted acquisitions. Previously, Mr. Calabria served as President of Gemini Consulting Group, Inc., a boutique consulting firm which specialized in providing consulting services to companies in multiple marker segments with a core focus directed towards capital structuring and investments, brand strategy and marketing, M&A activities, and operational efficiencies. Prior to this, Mr. Calabria was the VP of Operations for TrinTel Communications; the largest privately held Infrastructure Company in the wireless telecommunications industry. As part of the Company’s initial Senior Management team, which grew the company to a $350+ million valuation in under three years, Mr. Calabria specialized in managing joint venture agreements and strategic alliances as well as directing all subsidiary operations including regional sales, marketing, and business development practices. Prior to this, as the Director of Operations for Wireless Solutions, LLC, he helped facilitate the sale of the company to TrinTel Communications. Mr. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a BS in Management from Arizona State University.
Follow Don Calabria:
About Endonovo Therapeutics: Endonovo Therapeutics is a biotechnology company developing off-the-shelf regenerative products.
Clarissa Shen
COO of Q Bio
Clarissa Shen is Chief Operating Officer and Board Member at Q. She is an international executive and entrepreneur who enjoys scaling high-growth teams who are on a mission to change the world for good. Most recently, she was COO at Udacity, where she joined as the first business hire and helped grow the company from $0 to $100MM revenue run rate. She started her career in management strategy consulting at Monitor Group (now Deloitte Monitor) advising Fortune 500 executives and companies in Greater China, Southeast Asia, and Europe. In her past life, she has led a top 10 Google digital marketing team, managed an internationally-touring contemporary dance company, and co-founded a pioneering K-12 foreign language education start-up. Clarissa graduated magna cum laude from Williams College and has an MBA from Harvard Business School.
Follow Clarissa Shen:
About Q Bio: On a mission to build the first Clinical Digital Twin Platform and make it accessible to everyone
Sean Jeffries
Chief Operating Officer of Design Therapeutics
Sean Jeffries is the Chief Operating Officer at Design Therapeutics.
Follow Sean Jeffries:
About Design Therapeutics: Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders.
Bruce Given
Chief Operating Officer of Arrowhead Pharmaceuticals
Follow Bruce Given:
About Arrowhead Pharmaceuticals: Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Guy Snir
Co-Founder & COO of Clear Genetics
Follow Guy Snir:
About Clear Genetics, Invitae: Clear Genetics is a digital health company dedicated to the thoughtful integration of genetics into routine patient care.
Pamela Hudson
Chief Operating Officer & Center for Digital Health Innovation of University of California, San Francisco
Pamela Hudson is the Chief Operating Officer & Center for Digital Health Innovation at UCSF.
Follow Pamela Hudson:
About BayHealth Development, Gordon and Betty Moore Foundation, UCSF health, University of California, San Francisco, University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Kyle Giffin
Co-founder, Chief Operating Officer of LatchBio
Kyle Giffin is a Co-founder at Latch Bio.
Follow Kyle Giffin:
About LatchBio: Latch Bio builds and disseminates free to use data infrastructure for the the biocomputing revolution.
Anish Bhatnagar
Chief Executive Officer, President & Chief Operating Officer of Soleno Therapeutics
Dr. Bhatnagar was appointed as our Chief Executive Officer in February 2014. Prior to that, he served as our President and Chief Operating Officer. Dr. Bhatnagar joined us in 2006, and has held positions of increasing responsibility since then. Dr. Bhatnagar is a physician with over 15 years of experience in the medical device and biopharmaceutical industries. His experience spans development of biologics, drugs, drug-device combinations and diagnostic as well as therapeutic medical devices. His prior experience includes working at Coulter Pharmaceuticals, Inc. from 1998 to 2000 and Titan Pharmaceuticals, Inc. from 2000 to 2006. He is the author of several peer-reviewed publications, abstracts and book chapters. He obtained his medical degree at SMS Medical College in Jaipur, India and completed his Residency and Fellowship training in the U.S. at various institutions, including Georgetown University Hospital and the University of Pennsylvania.
Follow Anish Bhatnagar:
About Soleno Therapeutics: Soleno Therapeutics is a clinical-stage biopharmaceutical company
Chun Wu
Co-Founder and COO of iCarbonX
Chung Wu is Co-founder and COO of iCarbonX. Dr. Wu joined the Boston Consulting Group (BCG) in 2003. As the global Partner and Managing Director, Dr. Wu led her team to assist tens of multinational and domestic companies to formulate corporate strategy and improve business management. Early 2015, Dr. Wu joined the Beijing Genomics Institute as the Chief Operating Officer, overseeing manufacturing, marketing, and sales globally. Dr. Wu received B.S. degree in biology from Peking University and Ph.D. in genetics from Yale University.
Follow Chun Wu:
About iCarbonX: iCarbonX is a China-based artificial intelligence platform for health data company.
Sofia Elizondo
Co-Founder and COO of Brightseed
Sofia Elizondo is the Co-founder and COO at Brightseed.
Follow Sofia Elizondo:
About Brightseed: Brightseed features artificial intelligence that reveals powerful compounds hidden in nature.
Bryan Giraudo
Chief Financial Officer & COO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
Follow Bryan Giraudo:
About Gossamer Bio: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
David de Vries
Co-Founder and COO of Arine
David oversees overall company strategy, operations, sales, marketing and business development for Arine. Prior to Arine, David was the Director of Commercial Strategy and Development at Proteus Digital Health, where he oversaw partnerships, key elements of new product development and other strategic growth initiatives including the design and execution of the first value-based contracts for digital medicines. Before that, he worked at the RAND Corporation on the analysis and evaluation of several elements of the Affordable Care Act. When he’s not focusing on transforming healthcare through technology, he is most likely to be spotted at your local photography exhibit, neighborhood pickup basketball court, or by a large body of water attempting and failing some kind of watersport. David holds a Bachelor’s Degree in Neurobiology from Harvard and a Master’s Degree in Chemical Engineering and Biotechnology from the University of Cambridge.
Follow David de Vries:
About Arine: Arine optimizes medications and improves human health through data-driven clinical services.
Tao Fu
President, COO & Director of Zai Lab
Tao Fu has been our President & Chief Operating Officer since September 2018. Prior to joining Zai Lab, he worked with Portola Pharmaceuticals, where he served as Executive Vice President, Chief Commercial and Business Officer, responsible for commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Tao was Vice President and Head of Mergers & Acquisitions and Alliance Management at Bristol-Myers Squibb (BMS). At BMS, he was responsible for the company’s corporate development, alliance management and venture activities. Between 2003 and 2014, he held several leadership positions with increasing responsibilities at Janssen, the pharmaceuticals group of Johnson & Johnson, most recently as Vice President, Business Development, where he led global M&A activities. He also has experience in business development, commercial strategy and management consulting with McKinsey & Company, Becton Dickinson, etc. Tao holds an M.S. in biology from the University of Rochester and an M.B.A in finance and marketing from Vanderbilt University. He did his undergraduate studies in biology at Tsinghua University in Beijing, China and is a Chartered Financial Analyst (CFA).
Follow Tao Fu:
About Zai Lab: Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Pad (Padmanabh) Chivukula
Founder, CSO & COO of Arcturus Therapeutics
Padmanabh (Pad) Chivukula Ph.D., is Founder, Chief Scientific Officer, Chief Operating Officer and Director of Arcturus Therapeutics. He is responsible for Arcturus’ research and development activities, including clinical and non-clinical development and regulatory affairs for all of Arcturus drug products. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto Denko Technical Corporation, a pharmaceutical company, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto Denko.
Follow Pad (Padmanabh) Chivukula:
About Arcturus Therapeutics: Arcturus Therapeutics focuses on developing novel RNA therapeutics for the treatment of various diseases aiming at Rare Diseases.
Tayson Siegel
Chief Operating Officer of Xip
Follow Tayson Siegel:
About Xip: Xip produces disposable blood analyzers that wirelessly upload lab-quality clinical measurements in minutes.
Mary Z. Luo
COO, Chief Scientist of Amphastar Pharmaceuticals
Mary Z. Luo, Ph.D. has served as Chief Operating Officer for Amphastar Pharmaceuticals, Inc. and Chairman of the Board of Directors since its inception in 1996. She has also served as a Chief Scientist since 2005 and Corporate Secretary from 1996 through April 2004. As co-founder of both Amphastar Pharmaceuticals, Inc. and APCL, Dr. Luo has over 30 years of academic and practical experience in the field of chemistry. She provides scientific leadership through her research and activities in technology transfer, regulatory submission, intellectual property, clinical research, recruitment, and training. Dr. Luo is a professor emeritus of chemistry at California State Polytechnic University, Pomona and is named as the inventor on several U.S. and foreign patents. She received a Ph.D. in Chemistry from Princeton University and was a Post Doctoral Research Associate at the California Institute of Technology.
Follow Mary Z. Luo:
About Amphastar Pharmaceuticals: Amphastar Pharmaceuticals specialty pharmaceutical company that is engaged in the development, manufacture and marketing of generic.
Jun Yoon
Chief Operating Officer of ShouTi
Jun Yoon is the Chief Operating Officer at ShouTi.
Follow Jun Yoon:
About ShouTi: ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.
Stewart Roberts
Co-founder, President & COO of Biolinq
Stewart Roberts is the Co-founder, President, and COO of Biolinq.
Follow Stewart Roberts:
About Biolinq: Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.
Jared Tangney
Co-founder, President & COO of Biolinq
Jared Tangney joined Biolinq as Co-founder, President, and COO in November 2020. He earned a Doctor of Philosophy (Ph.D.) degree in Bioengineering and Biomedical Engineering at UC San Diego.
Follow Jared Tangney:
About Biolinq: Biolinq develops a wearable biosensor platform that is capable of measuring blood level information.
Stelios Tzannis
Founder and COO of Aeovian Pharmaceuticals
Stelios Tzannis is the Founder and COO of Aeovian Pharmaceuticals.
Follow Stelios Tzannis:
About Aeovian Pharmaceuticals, Delos Pharmaceuticals: Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases.
Suma Krishnan
Founder & Chief Operating Officer of Krystal Biotech
Suma Krishnan is the Founder and Chief Operating Officer at Krystal Biotech. She earned a degree of Master of Science in Organic Chemistry from Villanova University.
Follow Suma Krishnan:
About Krystal Biotech, Light Matters Foundation: Krystal Biotech provide significant clinical benefit for patients suffering from rare debilitating disorders..
Andrew Bartynski
Co-Founder and COO of ANA Therapeutics
Andrew Bartynski is the Co-Founder and COO of ANA Therapeutics.
Follow Andrew Bartynski:
About AesculaTech, ANA Therapeutics: ANA Therapeutics is a biotech company that is developing a novel coronavirus vaccine intended to save human lives.
James S. Marcelli
President & COO & Director of Lightwave Logic
Mr. Marcelli has served as President, CEO and director of Lightwave Logic since August 2008. He is responsible for the day-to-day operations of the company and its progress toward a fully functioning commercial enterprise. Over the last twenty years, Mr. Marcelli has served as the president and chief executive officer of multiple start-up and growth companies in high tech manufacturing and business services, including two companies that were founded by him. In addition, he has held senior management positions with several companies including Teradyne Corporation and Sanmina Corporation. Throughout his career, he has held positions in Engineering, Sales, Marketing, Operations and Finance. Mr. Marcelli has served on the boards of several non-profit corporations and also served on the Advisory Board of the University of Colorado, Colorado Springs Engineering School.
Follow James S. Marcelli:
About Lightwave Logic: Lightwave Logic is a research and development company focused on developing application-specific electro-optic polymers.
Wenkang Qi
Chief Operating Officer of VitalConnect
Wenkang Qi is the Chief Operating Officer at VitalConnect.
Follow Wenkang Qi:
About VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Sam Quezada
Co-founder & COO of CellSight Technologies
Sam Quezada has over 30 years experience in startups and high growth companies. Most recently he managed IP and corporate relations at MIPS Stanford. He has served in executive roles in various hardware companies managing operations, support, finance, QA, marketing and business development. His focus on customer needs and translation of the needs to product delivery led to successful exits in startups. He obtained a BS in Electrical Engineering and an MBA from Stanford.
Follow Sam Quezada:
About CellSight Technologies: CellSight is developing a suite of PET tracers targeted at visualizing immune response early in a patient’s immunotherapy regimen.
Keita Funakawa
COO of Nanome
As a scientifically minded artist, Keita grew up in Tokyo then moved to Honolulu where he attended middle and high school. As the lead programmer for his high school robotics team, he led his team to two time (2009,2010) state championships at the East Oahu VEX robotics competitions. As an award winning filmmaker, his film Foliage: Roots of the Tree Barrel won the 2014 HIFF (Hawaii International Film Festival) student showcase and was named San Diego Surf Film Festival’s Emerging Filmmaker. During my undergraduate career, after reading about Mt.Gox in late 2013, I found a new passion for cryptocurrencies and blockchain which made me switch my degree from Computer Science to Management Science (Quantitative Economics). Being the Assistant Curator for the UC San Diego Film Festival, I was exposed to VR since 2014. When I first experienced the google cardboard and the HTC vive, I decided that I could no longer be a painter when photography just got invented, sort of speak. This led me to learn as much as I could about VR. At the Festival I met Steve, who told me about his idea for Nanome (formerly NanoVR) in April 2015. Nanome is a software company that democratizes Science to accelerate innovation using Virtual Reality and Blockchain Technologies.
Follow Keita Funakawa:
About Nanome: Nanome is a virtual reality software company that offers a collaborative XR software platform for molecular design.
Van Dinh
Co-founder, Chief Operating Officer of Cloudbreak Therapeutics
Van Dinh is the co-founder and Chief Operating Officer of Cloudbreak Therapeutics. He has more than twenty years’ ‘experience in the pharmaceutical industry. He has worked in different scientific disciplines such as pharmacokinetics, toxicology, pharmaceutical development and analytical sciences and gained a vast amount of experience in drug development processes. During 18 years with Allergan he was involved in many drug development projects and helped to bring many drug development projects to successful commercial approvals such as Lumigan®, Combigan®, Acuvail®, Zymaxid®, Tazorac®, Ozudex®, Alphagan P®, Restasis®, Latisse®, and Lastacaft®. While at Allergan he managed departments such as In Vivo Science, Scientific Operations and Formulations and Analytical Sciences. He obtained a Master of Business Administration degree from Webster University and a Bachelor’s degree in Chemistry from the University of California, Irvine.
Follow Van Dinh:
About Cloudbreak Therapeutics: Cloudbreak Therapeutics is a clinical stage biotechnology company
David Doyle
Co-Founder and COO of DNA SEQ
David is a Co-Founder of a Los Angeles based technology group developing proprietary IP in three areas of digital technology that were designed to increase the efficiencies of the server side hardware infrastructure, enrich the user experience through client side software, and enhance search methodologies by implementing cognitive resources to the management of data.
Follow David Doyle:
About DNA SEQ: DNA SEQ offers reports that match a patient’s genomic profile to targeted therapies using crystallography-based filtering methodology.
Michon Pinnix
Chief Operating Officer of Chimera Bioengineering
Michon Pinnix is the Chief Operating Officer at Chimera Bioengineering.
Follow Michon Pinnix:
About Chief, Chimera Bioengineering: Chimera solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program of the immune system.
Nick Galli
Chief Operating Officer of Interline Therapeutics
Nick Galli is the Chief Operating Officer of Interline Therapeutics. Prior to that, he was the Chief Business Officer at CytomX Therapeutics.
Follow Nick Galli:
About Interline Therapeutics: Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Mitchell B. Frey
Co-founder & Chief Operating Officer of GENiSYSS
Co-founder and Chief Operating Officer (COO) Mitchell Frey has worked as a consultant with over 40 start-ups, hi tech manufacturers, research labs, and companies covering a wide range of projects including design, research, product development, manufacturing support, and building custom test equipment. Mitch has designed a range of products including electronic control systems for 3 generations of the Mars Rover program, Space Shuttle, Alpha Magnetic Spectrometer, Military manned and un-manned Aircraft, Missiles, armored personnel transports, as well as commercial Cochlear Implants, Surgical drill and saw systems, e-beam and sputtering control systems, etc. His expertise includes general business, product development and manufacturing.
Follow Mitchell B. Frey:
About GENiSYSS: GENiSYSS is a DNA vault that allows its users to store physical DNA and related personal and medical information on a device.
G. Bradley Cole
COO of Genomic Health
Follow G. Bradley Cole:
About Genomic Health: Genomic Health is a provider of genomic-based diagnostic tests that address overtreatment and optimal treatment of early-stage cancer.
Dan Kagan
Chief Operating Officer & VP Innovation (Strategy/Operations) of Scientist.com
Dan is a bioengineer who has worked extensively with life science start-up companies. Prior to joining Scientist.com, he advised startups at eBoost Consulting, started a company called ChemoTactics and was the CTO of the UC-San Diego 100K Entrepreneur Challenge. In 2012, Dan was selected as a Siebel Scholar. Dan received an M.S. and Ph.D in Bioengineering from Joseph Wang’s lab at UCSD, where he was a Gordon Scholar. He received a B.S. degree, summa cum laude, from Rutgers in 2006.
Follow Dan Kagan:
About Scientist.com: Scientist.com is a network of public and private e-commerce marketplaces that connect buyers and sellers of scientific research services.
Grace Wei
COO, Founder, PhD of Encellin
Follow Grace Wei:
About Encellin: Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics.
Eniko Fodor
COO of Verseon
Eniko Fodor serves as the Chief Operating Officer at Verseon. Eniko has guided Verseon’s technology and drug pipeline development and operational growth and has also overseen its finance and accounting functions through various stages. Previously, she was co-founder and COO of Pulsent Corp. An inventor of that company’s original technology, she was instrumental in growing the company and developing its products and technology. Eniko is an inventor on 25 patents and received her BS in physics from Universitatea Babes-Bolyai, Kolozsvár, Romania
Follow Eniko Fodor:
About Pulsent Corporation, Verseon: Verseon’s breakthroughs in computational chemistry, AI, & synthesis create novel pharmaceuticals. Atom by atom, we drive innovation.
Wendy S. Johnson
Chief Operating Officer of Reneo Pharmaceuticals
Wendy S. Johnson is a venture partner with ProQuest Investments, and the CEO of two San Diego-based companies, Aires Pharmaceuticals and Palkion. She has broad experience in the establishment and operations of venture-backed life science companies. Working with life science start-up companies since 1986, she has established a broad network of contacts including venture capital organizations, high level individuals involved in research and development as well as business development in the major pharmaceutical companies and biotechnology companies throughout the world. In addition to these business contacts, she is well-known in the technology transfer offices of many of the leading academic and research institutions in the U.S. and Europe. After leaving a ten-year career with the Food and Drug Administration she became involved in the biotechnology industry working in a number of start-up venture backed companies. She joined ProQuest Investments, a $1B life science venture fund as a venture partner in October 2005. In November 2006, she founded Aires Pharmaceuticals a pulmonary drug development company and secured Series A financing. In February 2007 she founded Palkion, Inc. a joint venture company with a Crystal Genomics, Inc. a public biotechnology company in South Korea, and secured series A financing. Prior to ProQuest she served as Senior Vice President, Corporate of Salmedix until its sale to Cephalon in May 2005. She has served as part of senior management teams in several San Diego-based life science companies since 1988. Ms. Johnson holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from the University of Maryland.
Follow Wendy S. Johnson:
About Gemini Advisors, Palkion, Reneo Pharmaceuticals: Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases.
Ignacio Willats
Co-Founder & COO of Mytos
Follow Ignacio Willats:
About Mytos: Mytos is building a fully-automated cell manufacture platform for Pharma
Graham Cooper
COO, CFO of Assembly Biosciences
Graham Cooper joined us as Chief Financial Officer in February 2013. Prior to joining us, during 2012, Graham Cooper was the Executive Vice President, Finance and Chief Financial Officer of Geron Corporation, a biopharmaceutical company focused on cancer therapies. From 2006 until 2011, Graham Cooper served as Senior Vice President, Chief Financial Officer and Treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity. From 1999 to 2006, Graham Cooper held positions of increasing responsibility including Director, Health Care Investment Banking, at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From August 1992 to January 1995, he worked as an accountant at Deloitte & Touche, and was previously a C.P.A. Graham Cooper holds a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.
Follow Graham Cooper:
About Assembly Biosciences, Beam Therapeutics: Assembly Biosciences, Inc. is a public biotechnology company and provider of oral biologic therapeutics.
Sanjiv Taneja
COO of FemtoDx, Inc.
Sanjiv Taneja serves as the Chief Operating Officer at FemtoDx. He is also an Advisor at Berkeley SkyDeck.
Follow Sanjiv Taneja:
About FemtoDx, Inc.: FemtoDx is a medical device company that transforms diagnostics with innovative technology.
Philip Lee
Co-Founder & COO of Senti Biosciences
Follow Philip Lee:
About Senti Biosciences: Senti Biosciences is a developer of a programmable biology platform for cancer therapies.
Paul Daruwala
Chief Operating Officer of Cidara Therapeutics
Paul Daruwala has over 22 years of experience in the biopharmaceutical industry and will lead Cidara’s commercial and business development strategy and execution. Prior to joining Cidara, Mr. Daruwala was at Bristol-Myers Squibb Company, where he served as Vice President of the U.S. Viral Hepatitis Franchise and was responsible for leading the U.S. launch in HCV and running the HBV business for BARACLUDE. Prior to Bristol-Myers Squibb, Mr. Daruwala served as Vice President Commercial & Strategic Management at Vertex Pharmaceuticals, where he helped lead the U.S. launch of INCIVEK for HCV. At the time, INCIVEK became the fastest drug launch to achieve blockbuster status. Mr. Daruwala had previously spent 18 years at Merck in U.S. and global commercial leadership roles in antivirals, antifungals, anti-inflammatory products, business development, managed markets and sales management. Among these, he led the global commercialization efforts for the first approved echinocandin antifungal drug, caspofungin acetate (CANCIDAS). Paul received his degree in pharmacy from the University of Kentucky.
Follow Paul Daruwala:
About Cidara Therapeutics, Cidara Therapeutics: Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics.
Shenda Baker
President, Chief Operating Officer of Synedgen
Shenda Baker joined Synedgen as President and CEO in 2019.Dr. Shenda Baker has more than 20 years of experience conducting, generating funds for, and directing chemistry, materials science, and biochemistry research. She provides scientific leadership, manages the intellectual property as well as the scientific and regulatory collaborations, and provides financial and organizational oversight at Synedgen. Previously, Dr. Baker was a professor of Chemistry at Harvey Mudd College from 1991-2014. She served on the Board of Directors of the Materials Research Society and has served on advisory boards with the National Institutes of Health, National Science Foundation and the Department of Energy. She is co-inventor on all of the Synedgen technology.
Follow Shenda Baker:
About Harvard Innovation Labs, Prisyna, Synedgen, Synspira: Synedgen develops novel therapies and products to reduce infection and inflammation of dermal, oral, mucosal, and ophthalmic surfaces.
Willis C. Lee
Chief Operating Officer of Emmaus Medical
Mr. Lee has more than 25 years of management and consulting experience with influential companies in the semiconductor and healthcare industries. Prior to joining Emmaus, Mr. Lee led worldwide sales and business development of Yield Dynamics’ product group at MKS Instruments. He joined the Comapany in 2009 and has served as Chief Operating Officer since May 2011. He has held various managerial and senior positions at companies including HPL, Syntricity and Reden & Anders, a subsidiary of United Healthcare that provides actuarial services including capitation and risk assessment analyses for healthcare insurance carriers. Mr. Lee received his B.S. and M.S. in Physics from University of Hawaii and University of South Carolina, respectively. He was a member of the American Physical Society, completed TQM/SPC programs, and has published papers in Nuclear Instruments and Methods.
Follow Willis C. Lee:
About Emmaus Medical: Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Alexander Schuth
COO & Head of Corporate Development of Denali Therapeutics
Alexander Schuth is the COO at Denali Therapeutics
Follow Alexander Schuth:
About Denali Therapeutics: Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
A. Taylor Bright
Co-Founder and Chief Operating Officer of Novoron Bioscience
Taylor Bright’s passion lies in the translation of exciting academic science into clinically viable commercial applications. As a co-founder of Novoron Bioscience, Taylor Bright has applied this passion into leveraging his academic and industry experience to advance Dr. Stiles’ discoveries out of UCSD and into Novoron Bioscience’s technology pipeline. His extensive research experience in cell biology, cell culture, and molecular biology is well-served by his competency in bioinformatics and computational biology. In addition, he has experience in protocol design and optimization as well as project management. Taylor earned a Ph.D. in Biomedical Science from UCSD and an A.B. from Princeton University.
Follow A. Taylor Bright:
About Novoron Bioscience: Biotechnology company developing pharmaceutical therapies for nerve regeneration in the central nervous system.
Douglas Bonhaus
Chief Operating Officer of Neuropore Therapies
Chief Executive Officer at Neuropore Therapies, Inc.
Follow Douglas Bonhaus:
About Neuropore Therapies, Neuropore Therapies: San Diego-based Neuropore, a biopharmaceuticals firm developing treatments for Parkinson’s disease.
Douglas Bonhaus
Chief Operating Officer of Neuropore Therapies
Chief Executive Officer at Neuropore Therapies, Inc.
Follow Douglas Bonhaus:
About Neuropore Therapies, Neuropore Therapies: San Diego-based Neuropore, a biopharmaceuticals firm developing treatments for Parkinson’s disease.
Mark Hazeltine
Chief Operating Officer of Exagen
Mark Hazeltine has served as our Chief Operating Officer since March 2021 and served in multiple key leadership roles including General Manager, Senior Vice President of Finance and Corporate Development, VP of Finance, and Sr. Director of Financial Planning & Analysis since 2015. Prior to joining Exagen, Mr. Hazeltine served as Director of Financial Planning and Analysis and Director of Financial Business Processes at CareFusion, a medical technology corporation. Mr. Hazeltine also worked in multiple management roles at multinational organizations including Kyocera and Qualcomm. Mr. Hazeltine received his Bachelor of Business Administration degree from the University of San Diego and Master of Business Administration degree from the Marshall School of Business at the University of Southern California.
Follow Mark Hazeltine:
About Exagen: Exagen is a patient focused, discovery-driven life science company serving patients affected by autoimmune rheumatic diseases.
Tamas Gorbe
Co-Founder and COO of Menten AI
Tamas Gorbe serves as a co-founder and COO at Menten AI.
Follow Tamas Gorbe:
About Menten AI: Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Jason Turner
COO of Venclose
Jason Turner serves as the Chief Operating Officer at Venclose where he is responsible for managing the daily activities of the company and leading its business planning and execution efforts.
Follow Jason Turner:
About Venclose: Venclose is a medical technology company that develops solutions for the treatment of venous insufficiency.
Kelly Wong
Co-Founder, COO, and Head of Biology of Via Nova Therapeutics
Kelly Wong is the Co-Founder, COO, and Head of Biology at Via Nova Therapeutics.
Follow Kelly Wong:
About Via Nova Therapeutics: Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections.
Michael Espinoza
Co-Founder and COO of Spectrum CannaLabs
Michael Espinoza is the co-founder and COO of Spectrum CannaLabs. He is also the director of UC Davis Health System.
Follow Michael Espinoza:
About Spectrum CannaLabs: Spectrum CannaLabs is an analytical testing laboratory that provides testing solutions for legal cannabis products.
Michael Leonard
Chief Financial Officer & Chief Operating Officer of Trigemina
Follow Michael Leonard:
About AtomBeam Technologies, Motif, Trigemina: Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.
Melinda Thomas
COO and Co-Founder of Octave Bioscience
Melinda Thomas currently works as Chief Operating Officer and Co-Founder at Octave Bioscience.
Follow Melinda Thomas:
About Octave Bioscience: Octave Bioscience an early stage molecular diagnostics company focused on neurodegenerative diseases and conditions.
Jeffrey Friedman
COO of DTx Pharma
Jeffrey Friedman is the COO of DTxPharma and managing partner at Friedman Bioventure.
Follow Jeffrey Friedman:
About DTx Pharma, Friedman BioVentures: DTx Pharma is developing technology that will unleash RNA-based therapeutics as the modality of choice.
Ben Vollrath
Chief Operating Officer of AMPRION
Ben is a seasoned life sciences executive and entrepreneur with over 15 years of experience in pharmaceutical and biotech companies. Ben also has an extensive background in developing biotech startups from inception to exit. Prior to Amprion, Ben served as CEO of Xetrios Therapeutics, an emerging biotech company focused on the development of novel therapeutics for immunological disorders and cancer. Xetrios was acquired by Kolltan Pharmaceuticals in 2014. Ben spent over 4 years as Entrepreneur in Residence at Avalon Ventures, a San Diego-based VC firm focused on developing early-stage life science companies. During his tenure with Avalon Ventures, Ben was a co-founder and senior member of the management teams of several biotech companies, including Afraxis (focused on CNS therapeutics, subsequently sold to Genentech for $187M), Carolus Therapeutics (focused on therapeutics for inflammatory diseases) and Otonomy (Nasdaq: OTIC, focused on therapeutics for diseases of the inner and middle ear). Prior to Avalon, Ben served as a scientist at Renovis, a San Francisco-based CNS drug discovery company and Merck. Ben also brings a broad experience in managing virtual and semi-virtual research programs. He is named inventor on over 40 patents or patent applications.
Follow Ben Vollrath:
About AMPRION: Breakthrough Biomarker Testing For Alzheimer’s, Parkinson’s and Lewy Body Dementia (LBD)
Nicholas Hodge
President & Chief Operating Officer of SeaChange Pharmaceuticals
Nick Hodge received a Ph.D. in Organic and Analytical Chemistry from Cornell University. He has held senior leadership positions at DuPont Merck, Caliper Technologies, Amphora Discovery (founder) and Ruga. Inventions from his corporate R&D labs include drugs for human clinical trials in several therapeutic areas, computational methods for drug design, and biological screening technology. Nick has extensive experience in the conception and execution of platform drug discovery startups, including commercialization strategy, fund-raising, business development, sales and management.
Follow Nicholas Hodge:
About SeaChange Pharmaceuticals: SeaChange develops chemoinformatic and statistical methods to uncover links between drug molecules and the biological targets.
Nicholas Hodge
President & Chief Operating Officer of SeaChange Pharmaceuticals
Nick Hodge received a Ph.D. in Organic and Analytical Chemistry from Cornell University. He has held senior leadership positions at DuPont Merck, Caliper Technologies, Amphora Discovery (founder) and Ruga. Inventions from his corporate R&D labs include drugs for human clinical trials in several therapeutic areas, computational methods for drug design, and biological screening technology. Nick has extensive experience in the conception and execution of platform drug discovery startups, including commercialization strategy, fund-raising, business development, sales and management.
Follow Nicholas Hodge:
About SeaChange Pharmaceuticals: SeaChange develops chemoinformatic and statistical methods to uncover links between drug molecules and the biological targets.
Ernest H. Pfadenhauer
Co-founder & COO of EPIOMED THERAPEUTICS
Mr. Ernest H. Pfadenhauer, also known as Ernie, is Co-Founder and Chief Operating Officer of Epiomed Therapeutics, Inc. Mr. Pfadenhauer is Co-Founder of Cenomed, Inc. and serves as its Vice President of Pharmaceutical Development. Mr. Pfadenhauer is the Founder of Cenomed BioSciences LLC and serves as its Vice President of Pharmaceutical Development. He has served as a consultant to the pharmaceutical industry, assisting principally in the manufacturing and controls area of new drug development. From 1996 to 2002, Mr. Pfadenhauer served as Director of Chemistry Research at NeoTherapeutics, Inc. In this position he was responsible for GMP synthesis and formulation of CNS and oncology drugs, compilation of NeoTherapeutics, Inc., Manufacturing and Controls sections of regulatory submissions, management of new drug pharmacokinetics, metabolism, and bioanalytical development, and was primary responsibility for biopharmaceutical areas of drug discovery. From 1987 to 1996, Mr. Pfadenhauer was employed in various positions as a research and project scientist at Baxter Healthcare Corporation, working in the clinical chemistry diagnostic, instrument design, and bioprosthetic heart valve development areas. While at Baxter, he was directly responsible for the design, manufacturing, and post-launch support of several successful commercial products. From 1970 to 1987, Mr. Pfadenhauer was employed at Newport Pharmaceuticals, where he served as the Supervisor of Quality Control, and later a Senior Research Scientist. During that period, he was involved in the analytical, pharmacokinetic, and metabolism areas of new drug development. Mr. Pfadenhauer serves as a faculty appointment at the University of California, Irvine. Mr. Pfadenhauer holds a B.S. and M.A. degree in Physical Chemistry from the University of California, Santa Barbara, where he graduated Cum Laude and was awarded the highest honor in the Chemistry Department.
Follow Ernest H. Pfadenhauer:
About EPIOMED THERAPEUTICS: Epiomed Therapeutics is focused on the discovery and development of novel anti-emetic compounds for both the human and veterinary markets.
Ryan Swoboda
Co-Founder and Chief Operating Officer of NAVAN Technologies
Ryan Swoboda co-founded NAVAN, Inc. in 2016 while conducting work with the Melosh Group at Stanford University, focusing on material synthesis and characterization. Ryan received his M.S. in Materials Science from Stanford University and his B.S. in Materials Science and Engineering (focus: NanoScience) also from Stanford. Having been a first-generation college student, Ryan understands the power of education and increased access to new technologies. In addition to his role as COO, Ryan is Principal Investigator of NAVAN’s Small Business Technology Transfer Program Phase II grant (award no. 1759075) funded by the National Science Foundation. In his spare time, Ryan enjoys conducting science demonstrations for low-income students in the local community.
Follow Ryan Swoboda:
About NAVAN Technologies: NAVAN Technologies is a privately-held biotechnology company enabling the development of next generation cell and gene therapies
Bruce Capagli
COO of Precision Disposable Products
Follow Bruce Capagli:
About Precision Disposable Products: PDP or Precision Disposable Products offers high quality, cost efficient, medical products.
Russ DeLonzor
COO & President of Raydiant Oximetry
Russ DeLonzor is the President and Chief Operating Officer of Raydiant Oximetry.
Follow Russ DeLonzor:
About Raydiant Oximetry: Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth.
Matt Mayes
COO of Sway
Matthew Mayes currently works as Co-Founder and COO at Sway.
Follow Matt Mayes:
About Sway: Sway offers regenerative design solutions for plastic pollution using seaweed to create compostable replacements for single-use plastics.
Michael Fero
President and COO of TeselaGen
Michael Fero is the Founder and President at TeselaGen Biotechnology.
Follow Michael Fero:
About TeselaGen: TeselaGen Biotechnology develops DNA design and assembly tools for biology.
Ulrike Hodges
COO of SafeTraces
Follow Ulrike Hodges:
About SafeTraces: SafeTraces provides on-food traceability solutions that trace the product, not the package.
Bork Balkan
COO of Bebaas Inc
Bork Balkan is the Chief Operating Officer at Bebaas Inc.
Follow Bork Balkan:
About Bebaas Inc: Bebaas Inc. is a California corporation founded in June, 2004 and based in Newport Beach, California.
Grace Xiaolu Yang
Chief Operating Officer and Vice President of Research, Co-Founder of Filtricine
Follow Grace Xiaolu Yang:
About Filtricine: Filtricine provides new solution to cancer care via Targeted Nutrients Deprivation.
Kevin Guo
COO of Matregenix
Kevin Guo currently works as Chief Operating Officer at Matregenix, Inc. He is also a Project Manager at American Technologies, Inc.
Follow Kevin Guo:
About Matregenix: Matregenix is a medtech company offering advanced nanofibrous materials for medical applications.
Krzysztof Appelt
Founder & Chief Operating Officer of Prevacept Infection Control
Dr. Appelt is a seasoned bio-technology scientist and executive with over 25 years of management experience in the biopharmaceutical industry. He has had extensive experience in the discovery and development of antiviral, antibacterial and anticancer chemotherapeutic agents. Dr. Appelt lead a multidisciplinary team at Agouron Pharmaceuticals which discovered and developed ViraceptTM – an innovative AIDS therapy, and several other compounds discovered using structure-based approached pioneered by Agouron. After Agouron’s acquisition by Warner-Lambert and subsequent merger with Pfizer, Dr. Appelt served as Global Head of Ophthalmology in both organizations. From 2001 to 2005 Dr. Appelt served as Executive VicePresident and Chief Technology Officer at Quorex Therapeutics, a company focused on the discovery of antibacterial and antibiofim agents. Dr. Appelt founded Great Lakes Pharmaceuticals in 2006. Dr. Appelt received his undergraduate degree in Physiology from Poznan University in Poland and his Ph.D. in Biophysics from the Max Planck Institute in West Berlin. Before joining Agouron Pharmaceuticals in 1987 he was Assistant Professor in Chemistry Department in University of California in San Diego. Dr. Appelt is a co-author of 57 peer reviewed publications and co-inventor of several patents.
Follow Krzysztof Appelt:
About Prevacept Infection Control: Prevacept Infection Control is a clinical-stage company focused on developing.
Bill Torres
Chief Operating Officer of Advanced BioCatalytics
Follow Bill Torres:
About Advanced BioCatalytics: Advanced BioCatalytics is a technology and product development that develops industrial biotechnology products.
Vaughn Ostland
VP/COO of Intrinsic LifeSciences
Follow Vaughn Ostland:
About Intrinsic LifeSciences: Intrinsic LifeSciences LLC, a life sciences company, develops in vitro diagnostic devices for clinical medicine applications
Rex Peters
Founder & Chief Operating Officer of Relievant Medsystems
Founder & Chief Operating Officer at Relievant Medsystems.
Follow Rex Peters:
About Relievant Medsystems: Relievant provides patients with low risk therapy that affords the ability to alleviate their back pain.
Michael Wood
Founder & COO of OncoMyx Therapeutics
Michael Wood is a Founder and Chief Operating Officer at OncoMyx Therapeutics.
Follow Michael Wood:
About OncoMyx Therapeutics: OncoMyx Therapeutics develops oncolytic immunotherapies to orchestrate an immune response and treat cancer.
Toshi Maruyama
Founder and COO/CSO of Abwiz Bio
Follow Toshi Maruyama:
About Abwiz Bio, Chiba University: We provide researchers world-wide with top-quality monoclonal antibodies
Lei Jin
Chief Operating Officer of Wuxi Biortus Biosciences
Lei Jin is the Chief Operating Officer at Wuxi Biortus Biosciences.
Follow Lei Jin:
About Wuxi Biortus Biosciences: Wuxi Biortus Biosciences is an innovation-driven contract research organization committed to high-quality R&D services in drug discovery.
Paul Larson
President, Chief Operating Officer & Director of Daylight Solutions
Paul Larson is a cofounder of Daylight Solutions and serves as the company’s President and COO. He is a seasoned executive with over 25 years’ experience managing business operations and developing leading-edge technologies. Mr. Larson has held senior management positions with successful start-ups such as San Diego-based Applied Micro Circuits Corporation (AMCC), and Qualcomm Inc. As Director of ASIC Programs for Qualcomm, Mr. Larson contributed significantly to the company’s early efforts to establish a commercially viable ASIC division, generating over $600M in revenue during its third year. Mr. Larson also contributed to business operations of larger, global companies such as Ericsson, where he was Director of Business Management. Mr. Larson began his career as an Electrical Engineer with Motorola’s Integrated Circuits Research Applications Laboratory (MICARL). He holds a BSEE from the United States International University and an MBA from San Diego State University.
Follow Paul Larson:
About Daylight Solutions: Daylight Solutions manufactures molecular detection and imaging instruments for diagnostics, homeland security, military and more.
Tom Myers
Chief Operating Officer of PURE Bioscience
Tom Myers has over 40 years of food industry experience focusing on operations management, quality control and assurance, research and development, product and process development, plant design and construction, food safety and regulatory compliance. Prior to joining PURE Bioscience, Mr. Myers served as the President and Principal of Idaho Milk Products where he built a $105 million green field dairy proteins plant and launched a worldwide business with revenues in excess of $200 million annually. Mr. Myers has also held executive management roles at Weider Nutrition International, Puritan Quartz Pharmaceuticals, FruitSource Associates and FruitSource Confections, Nancy’s Specialty Foods, Izaki Glico and Berkshire Hathaway Corporation (See’s Candies and See’s Candy Shops). Mr. Myers holds a Bachelor of Science degree from California State University Long Beach. As EVP, Technical Support Services, Mr. Myers leads the implementation and application of PURE’s SDC technology in customer facilities through problem identification and solution development, custom protocol development and training.
Follow Tom Myers:
About PURE Bioscience: PURE Bioscience develops and markets technology-based bioscience products that provide non-toxic solutions to global health challenges.
Dave Allen
COO of AltAir Fuels
Follow Dave Allen:
About AltAir Fuels: AltAir Fuels develops and operates projects for the production of low carbon fuels and chemicals derived from sustainable feedstocks.
Amy Curran
Chief Operating Officer of ZeaKal
Dr. Curran brings over fifteen years of industry and research leadership in the commercialization of biotech crops and industrial microbes. Dr. Curran joins ZeaKal through the acquisition of Algenetix where she was the Chief Technology Officer and managed the company’s high oil biomass, yeast and algae programs. Prior to Algenetix, Dr. Curran was with Rincon Pharmaceuticals, where she developed high throughput strategies to generate transgenic algal lines expressing therapeutic proteins. When Sapphire Energy acquired Rincon, Dr. Curran headed up research programs in developing transformation systems for novel industrial algal strains focused on the production of commercial bio-oils. Dr. Curran graduated summa cum laude from San Diego State University with a degree in biology and has a Ph.D. in plant molecular biology from the University of California, San Diego. She has completed three postdocs at The Scripps Research Institute, The University of Western Australia and The University of Nevada, Reno.
Follow Amy Curran:
About ZeaKal: Plant traits innovator helping crops capture more carbon and sunlight, leading to healthier, nutrient-rich food and feed.
Michael Dale
Co-Founder, President, Chief Operating Officer of Personalized Stem Cells
Michael Dale is the Co-Founder, President, and Chief Operating Officer at Personalized Stem Cells.
Follow Michael Dale:
About Personalized Stem Cells: Personalized Stem Cells is a Biotechnology company that provides quality stem cell processing services.
Michael Dale
Co-Founder, President, Chief Operating Officer of Personalized Stem Cells
Michael Dale is the Co-Founder, President, and Chief Operating Officer at Personalized Stem Cells.
Follow Michael Dale:
About Personalized Stem Cells: Personalized Stem Cells is a Biotechnology company that provides quality stem cell processing services.
Tom Gruber
COO and CFO of CDx Life
Tom has over 20 years of experience in financial and senior executive management from well known, publicly traded technology companies. He has worked as the CFO for Western Digital and as the CFO and COO for I/O Magic. Tom holds an MBA from Pepperdine University.
Follow Tom Gruber:
About CDx Life: MyDx (My Diagnostic) is the world’s first portable analyzer for everyone – a simple and affordable device.
Brian Hilbush
Chief Operating Officer of ModGene Pharma LLC
Follow Brian Hilbush:
About ModGene Pharma LLC: ModGene Pharma, LLC is a preclinical stage pharmaceutical company developing therapeutics for the prevention of Alzheimer’s disease.
Brian Hilbush
Chief Operating Officer of ModGene Pharma LLC
Follow Brian Hilbush:
About ModGene Pharma LLC: ModGene Pharma, LLC is a preclinical stage pharmaceutical company developing therapeutics for the prevention of Alzheimer’s disease.
Ian Lamont
COO of Pontic Technology
Ian does senior consulting projects for TLG Marketing. Ian joined his son’s at TLG in June after more than 40 years of senior executive operational leadership experience, including the last two decades as CEO of companies ranging from Fortune 500 to a start-up. Ian is a respected strategic business and market planner, who has created and launched numerous businesses and successful products in the energy, media, e-commerce and service areas. Known for his leadership and his ability to come into difficult situations with energy, passion and focus, Ian creates a productive culture for change while involving other key leaders in developing a strategic plan for a sustainable turnaround and innovative growth opportunities, whether it is people, teams or revenue. A former boss perhaps best describes Ian “You consistently amaze me, not only in the financial results you get, but especially because your people respect, admire and love you. I would just settle for respect from mine.” Despite a career that not only exceeded his goals, but his dreams, Ian is most proud of his extraordinary wife of 40 years, Oksanna, his son’s Evan and Shawn, and the men they have grown to become, and their own extraordinary wife’s Hannah, an outstanding estate and trust attorney and Lisa, a superb technologist and educator.
Follow Ian Lamont:
About Pontic Technology: Patented thermal disinfection system technology for germ-free, clean water solutions